Idecabtagene Vicleucel: The Ultimate CAR T-Cell Therapy for Multiple Myeloma?

Pouya  Safarzadeh Kozani; Pooria Safarzadeh Kozani; Abdolkarim Sheikhi

doi:10.5812/tms.123859

Idecabtagene Vicleucel: The Ultimate CAR T-Cell Therapy for Multiple Myeloma?

authors:

Pouya Safarzadeh Kozani ^{#
1} , Pooria Safarzadeh Kozani ^{#
2} , Abdolkarim Sheikhi ^{3
, *}

1 Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

2 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

# These authors are contributed equally as the first author.

Trends in Medical Sciences: Vol.2, issue 1; e123859

published online: April 9, 2022

article type: Letter

received: March 5, 2022

revised: March 28, 2022

accepted: March 28, 2022

DOI: https://doi.org/10.5812/tms.123859

how to cite: Safarzadeh Kozani P , Safarzadeh Kozani P, Sheikhi A. Idecabtagene Vicleucel: The Ultimate CAR T-Cell Therapy for Multiple Myeloma?. J Adv Immunopharmacol. 2022;2(1):e123859. https://doi.org/10.5812/tms.123859.

Keywords

Idecabtagene Vicleucel Multiple Myeloma CAR T-Cell Therapy

Footnotes

Authors' Contribution: PS, PS, and AS contributed to writing and revising this manuscript.
Conflict of Interests: The authors declare no conflict of interest.
Ethical Approval: IR.DUMS.REC.1400.006 (Link: ethics.research.ac.ir/EthicsProposalView.php?id=192621)
Funding/Support: This letter was financially supported by Dezful University of Medical Sciences, Dezful, Iran (grant no.: IR.DUMS.REC.1400.006).

References

1.
Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(5):332. [PubMed ID: 33790473]. https://doi.org/10.1038/d41573-021-00063-1.
2.
Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther Adv Hematol. 2021;12:20406207211019600. [PubMed ID: 34104374]. [PubMed Central ID: PMC8170343]. https://doi.org/10.1177/20406207211019622.
3.
Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-99. [PubMed ID: 26370838]. [PubMed Central ID: PMC4976846]. https://doi.org/10.2217/imt.15.77.
4.
Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma. Semin Oncol Nurs. 2017;33(3):225-36. [PubMed ID: 28688533]. https://doi.org/10.1016/j.soncn.2017.05.012.
5.
FDA. FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma. U. S. Food & Drug; 2021, [cited 14 February 2022]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma.

comments